Define what you're actually buying before you compare distributors
"Regenerative biologics distributor" covers a wide range of products that do not share a single regulatory framework. A distributor's catalog might include Wharton's jelly products, offered under the supplier's HCT/P framework, alongside extracellular vesicle or exosome products. FDA has stated there are no FDA-approved exosome products; these are generally regulated as biologic drugs under section 351 of the Public Health Service Act, and purchase and clinical-use decisions for them belong to the physician and their own regulatory counsel. Whether a specific Wharton's jelly intended use qualifies solely under section 361 depends on all applicable criteria in 21 CFR 1271.10; that determination also belongs to the clinic and its counsel.
Before comparing two distributors, confirm you are comparing like categories. A distributor with a strong tissue allograft program is not automatically positioned the same way on exosome products, and vice versa, because the documentation and regulatory questions differ by product family.
What to request before comparing distributors on price
Compare distributors on documentation rather than on a sales conversation. For tissue allografts, ask each distributor for its donor eligibility summary, the processing timeline it documents between recovery and processing, and the standards it describes its processing as following. PB processes tissue within 48 hours of recovery; ask other distributors to document their own window for comparison.
For every product family, ask for a certificate of analysis tied to a unique lot identifier, confirmation that lots are held in quarantine until third-party sterility testing and internal release criteria are met, and, for extracellular vesicle products, the underlying characterization data rather than a summary claim.
Look at how a distributor talks about its own products
In 2026, FDA sent warning letters to several distributors of private-label Wharton's jelly and exosome products, citing disease claims made on company websites and social media. FDA's enforcement position treats a distributor's own marketing, affiliate content, and social posts as evidence of a product's intended use, and a "research use only" disclaimer does not change that reading if the same product is promoted for clinical use elsewhere.
Review a supplier's public claims with counsel alongside product documentation; FDA considers marketing evidence of intended use. Reviewing a prospective distributor's own website and social accounts for this pattern is part of standard due diligence.
Logistics and inventory operations
Ask how each distributor handles cold chain for cryopreserved products: whether they are frozen using a slow-rate process, stored at -80 degrees Celsius, and shipped overnight on dry ice in validated containers, and what the distributor's process is if a shipment arrives outside the expected temperature range.
Ask how lot traceability is maintained once product reaches your clinic. A distributor that supports tracking usage by lot at the patient record level is supporting your own record-keeping obligations, not just its own.
Support structure and account verification
Confirm that the distributor restricts orders to licensed professionals and verifies accounts against an NPI number before processing a first order. Ask whether the distributor offers access to physician-level conversations focused on product documentation, distinct from clinical or dosing advice, and confirm in writing that it is positioned that way.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
A short framework for comparing two distributors side by side
Score each distributor on four dimensions: documentation completeness for the specific product family you need, consistency between its marketing and the regulatory framework it claims, logistics and traceability support, and account verification practices.
Frequently asked questions
Should the same evaluation apply to a tissue allograft distributor and an exosome distributor?+
The core documentation habits are similar, but the regulatory questions differ. Whether a Wharton's jelly product qualifies solely under section 361 depends on its specific intended use and all applicable criteria in 21 CFR 1271.10. Exosome products are generally regulated as biologic drugs under section 351, and FDA has stated there are no FDA-approved exosome products. Review both determinations with your regulatory counsel.
Why does a distributor's own marketing matter to a buyer, not just to the distributor?+
FDA's 2026 warning letters treated distributor marketing and affiliate content as evidence of a product's intended use. Review a prospective distributor's public claims with your own counsel alongside its product documentation.
What single document should we request first from any new distributor?+
The certificate of analysis for the specific lot you intend to purchase, tied to a unique lot identifier. It is the fastest way to tell a documented program apart from a marketing-led one.
Can this framework tell us whether a product qualifies under section 361 or section 351?+
No. That determination belongs to your clinic and your own FDA regulatory counsel for your specific intended use. This framework helps you compare distributors on documentation and posture; it is not legal advice.